South Korea approves first biosimilar Remsima from Celltrion to compete with Remicade - 24-Jul-2012
South Korea has granted the first approval worldwide to a biosimilar version of Johnson & Remicade (infliximab) from Johnson & Johnson/Merck Inc. ).The regulatory clearance is for Remsima (CT-P13) from Celltrion and is also the first to be given anywhere to a biosimilar monoclonal antibody.Remsima may also be launched by the end of the year in a number of Asian and South American markets,
Related News
CHMP rejects Xeljanz (Pfizer) as a treatment for Rheumatoid Arthritis
Fostamatinib (AstraZeneca) mixed results in OSKIRA-1 trial for RA
Study shows RoActemra/Actemra (Genetech/Roche) superior to Humira in achieving remission in Rheumatoid Arthritis patients
SOBI and Savient Pharma to co -promote Kineret in USA
Positive results in Phase III trial of Xeljanz (Pfizer) in patients with Rheumatoid Arthritis
Antares Pharma files Otrexup at FDA for Rheumatoid Arthritis
Phase IIb report of fostamatinib (AstraZeneca) OSKIRA-4 trial for RA
FDA approves Xeljanz (Pfizer) to treat Rheumatoid Arthritis
Related Rheumatology Information
Rheumatology Clinical Guidelines
Clinical practice guideline for the assessment and prevention of falls in older people
NICEOsteoarthritis: National clinical guideline for care and management in adults
NICERheumatology Clinical Trials
A Retrospective Observational Study on the Use of Biologics in Monotherapy in Patients With Rheumatoid Arthritis
Clinicaltrials.gov 11 April 2013A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis
Clinicaltrials.gov 10 April 2013Rheumatology Medical Journal Abstracts
Which Patients Are Most Likely to Benefit From Total Joint Arthroplasty?
Arthritis & Rheumatism 23 April 2013Variants in RUNX3 Contribute to Susceptibility to Psoriatic Arthritis, Exhibiting Further Common Ground With Ankylosing Spondylitis
Arthritis & Rheumatism 23 April 2013Rheumatology Medical Apps
Miniatlas Osteoporosis
£1.49
Rheumatoid Arthritis
£6.19
Related Rheumatology Drugs
- METOJECT 50 MG/ML SOLUTION FOR INJECTION
- ORENCIA 125 MG SOLUTION FOR INJECTION (PRE-FILLED SYRINGE)
- VIRORMONE INJECTION
- DIDRONEL PMO
- ESTRADOT TRANSDERMAL PATCH
- CELEBREX 200 MG CAPSULE
- LODOTRA® 1 MG, 2 MG AND 5 MG MODIFIED-RELEASE TABLETS
- NUVELLE CONTINUOUS
- VIMOVO 500 MG/20 MG MODIFIED-RELEASE TABLETS
- EVOREL 25, 50, 75 & 100 PATCHES
- ACTONEL COMBI
- EVISTA 60MG FILM-COATED TABLETS
- ACTONEL 30MG FILM-COATED TABLETS
- PROTELOS
- IBANDRONIC ACID 150MG FILM-COATED TABLETS
- ETOPAN XL 600 MG TABLETS
- TRISEQUENS® FILM-COATED TABLETS
- FABLYN
- ACTONEL 5 MG FILM-COATED TABLETS
- NAPROXEN 500 MG TABLETS
- VAGIFEM 25 MICROGRAMS FILM-COATED TABLETS
- CALCIUM-SANDOZ SYRUP
- KALCIPOS-D 500 MG/ 800 IU CHEWABLE TABLETS
- PREMPAK-C
- PROLIA
- EVOREL CONTI
- ACLASTA 5 MG SOLUTION FOR INFUSION
- NABUMETONE TABLETS 500MG
- NAPRATEC OP
- ENBREL 25 MG POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
- BONVIVA 150MG FILM-COATED TABLETS
- ESTRING
- NAPROXEN TABLETS 250MG
- LEFLUNOMIDE WINTHROP 20MG TABLETS
- HUMIRA PRE-FILLED PEN, PRE-FILLED SYRINGE AND VIAL
- CALCICHEW-D3 500 MG/400IU CAPLETS
- FASTURTEC
- FOSAMAX TABLETS
- CIMZIA 200 MG SOLUTION FOR INJECTION
- EVOREL SEQUI
- ALENDRONIC ACID 70MG TABLETS
- ACTONEL ONCE A WEEK
Advert for Healthcare Professionals only